News

WHAT'S NEW

Mon, February 26, 2018

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE). Designed for clinicians who provide nutrition support, the series address a knowledge gap between best practice recommendations and current practices in parenteral nutrition (PN).  "Lipids provide energy and essential fatty acids, and ASPEN's survey results demonstrate a need for a better understanding of ILE provision in current practice,"said Seema Kumbhat, M.D., senior vice president and regional medical director at Fresenius Kabi in North America. "This video series is designed to educate healthcare providers on ILE best practices, such that optimal nutrition can be delivered to patients who need it.'  For more on this series, click here.

Remifentanil Hydrochloride for Injection CII Now Available : First-to-Market Alternative to ULTIVA® "Fresenius Kabi has been investing significantly in product development over the last several years, and plans to launch multiple generic injectable products in the U.S. this year," said John Ducker, president and CEO of Fresenius Kabi USA.  For the press release, click here

Bortezomib for Injection: First available IV administration alternative to VELCADE® Bortezomib for Injection for intravenous use is indicated for the treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.  Tor the press release, click here.

Wed, January 10, 2018

Exicure, Inc. announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures. With this investment, the company has raised a total of approximately $31.5 million in this current round.

"Nucleic acid therapeutics hold great promise because they target the underlying genetic source of disease," said Dr. David Giljohann, Chief Executive Officer of Exicure. "Toxicity and delivery have been the primary challenges for companies seeking to use nucleic acids in drug development. Our SNA technology seeks to overcome these challenges and to change the cost curves and development timelines of highly targeted medicines. We are advancing a pipeline of drugs for a broad range of chronic conditions and orphan diseases in dermatology, ophthalmology, respiratory and gastric disorders, and solid tumors. We welcome this new round of investors in Exicure as they bring great insight into rapidly emerging markets for our products."

"As we look to the next generation of innovative pharmaceuticals, we clearly see a major role for nucleic acid therapies that regulate genes and enhance the immune system to combat disease," said Dr. Li You Xin, Senior Vice President and head of R&D of Luye Pharma Group. "The team at Exicure has made tremendous strides in unlocking the potential of these highly-targeted medicines."

NEWS ARCHIVES

January 2018

Exicure Funding

Exicure, Inc. announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager... Read on >

August 2017

NuMat Technologies & Versum Materials

Versum Materials, Inc., a leading global materials supplier to the semiconductor industry, and NuMat Technologies, a pioneer in the design and... Read on >

July 2017

Check out Mid Year SKOKIEBIZ

2017 has brought several new notable rankings for the Village.  ... Read on >

June 2017

Northwestern launches Ronald and JoAnne Willens Center for Nano Oncology

Led by Chad A. Mirkin, George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and director of the IIN, the Willens... Read on >